Metabolic homeostasis in mammals is tightly regulated by the complementary actions of
insulin and glucagon. The secretion of these hormones from pancreatic β-cells and α-cells …

Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities,
mainly in those individuals who develop cardiovascular diseases, type 2 diabetes …

With an increasing prevalence of obesity, there is a need for new therapies to improve body
weight management and metabolic health. Multireceptor agonists in development may …

Diabetes mellitus is a major public health problem, affecting about 10% of the population.
Pharmacotherapy aims to protect against microvascular complications, including blindness …

Gut hormones have many key roles in the control of metabolism, as they target diverse
tissues involved in the control of intestinal function, insulin secretion, nutrient assimilation …

To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease,
affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available …

Chronic, excessive neuroinflammation is a key feature of neurodegenerative diseases such
as Alzheimer's disease (AD) and Parkinson's disease (PD). However, neuroinflammatory …

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing
need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) …

The evolution of glucagon has seen the transition from an impurity in the preparation of
insulin to the development of glucagon receptor agonists for use in type 1 diabetes. In type 2 …

Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …